GSK (GSK) said Monday that the European Medicines Agency has agreed to review its prefilled syringe version of Shingrix, a vaccine for the prevention of shingles.
The company said the prefilled syringes do away with the need to mix separate vials before jabs.
The regulatory review follows the Jan. 8 US Food and Drug Administration acceptance of the prefilled syringes, the company said.
GSK said it is also considering submitting the product for review in other markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.